Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized liposomal amphotericin B for rescue treatment of invasive pulmonary or sinus fungal infections
2006-005031-21Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in Invasive fungal infection of the respiratory tract (IFI), Acute Invasive Aspergillosis and Sinonasal mycosis, sponsored by Istituto Giannina Gaslini. Primary endpoint: Safety of nebulized liposomal amphotericin B. Started Nov 2006; status: completed.
02
Drugs
amphotericin b
03
Conditions
Invasive fungal infection of the respiratory tract (IFI)Acute Invasive AspergillosisSinonasal mycosis
Beyond the preview
Go deeper on 2006-005031-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005031-21.